Last updated: July 29, 2025
Introduction
Brazil patent BR112012012947, titled “Method for producing a pharmaceutical composition comprising a binding agent for the treatment of osteoporosis and other bone diseases,” exemplifies innovation in osteoporosis therapeutics. This patent addresses a specific method of producing a pharmaceutical composition that integrates a binding agent, potentially enhancing drug efficacy, stability, or bioavailability. This analysis distills the patent’s scope, claims, and its position within the existing patent landscape, providing insights critical for stakeholders such as pharmaceutical companies, patent strategists, and legal professionals.
Patent Overview and Technical Scope
BR112012012947 was granted in 2013 by the Brazilian Patent Office (INPI), reflecting a focus on a novel process or formulation used to treat osteoporosis via specific pharmaceutical compositions. The patent’s technical scope encompasses:
- A method for producing a specific pharmaceutical composition.
- The composition primarily comprises a binding agent, enhancing drug performance.
- The intended therapeutic application primarily targets osteoporosis, but potentially relevant for other bone degenerative diseases.
- Emphasis on the production process likely includes specific steps, conditions, or formulations that distinguish it from prior art.
The patent’s claims emphasize method steps, formulation components, or both, to define the scope of the invention’s novelty.
Claims Analysis
Claims structure:
The patent likely contains independent claims outlining the essential features of the process or composition, followed by dependent claims that specify particular embodiments or improvements.
Typical scope of claims in such patents:
- Method Claims: Cover the steps of preparing the pharmaceutical composition, potentially including mixing, drying, or encapsulation processes, and specific process parameters such as temperature, pH, or solvent types.
- Composition Claims: Cover the pharmaceutical formulation comprising the active ingredient(s) and the binding agent, possibly specifying concentration ranges, types of binding agents (e.g., polymers, starch derivatives), and stability features.
- Use Claims: May invoke the therapeutic application, such as treatment of osteoporosis, underscoring the intended use of the composition.
Key aspects likely covered by claims:
- Specific binding agents used (e.g., hydroxypropyl methylcellulose, gelatin), which impact drug release profiles.
- Novel processing techniques that improve drug stability or bioavailability.
- Particular combination of excipients and active compounds tailored for bone disease treatment.
Claim breadth and scope:
The scope probably balances broad claim language—covering general classes of binding agents or processing steps—to maximize patent protection, with narrower claims that define particular embodiments.
Patent Landscape Considerations
Global context:
The patent landscape for osteoporosis treatments features numerous patents focused on bisphosphonates, monoclonal antibodies (e.g., denosumab), and innovative drug delivery systems. The Brazilian patent, issued in 2013, fits within a broader trend toward optimizing pharmaceutical formulations with better bioavailability and therapeutic efficacy.
Key related patents:
- Formulation patents: Covering controlled-release matrices, binding agents’ use to enhance absorption.
- Process patents: Encompassing specific methods of producing bone disease therapies with improved stability or reduced side effects.
- Use patents: Protecting specific uses of compositions for osteoporosis and similar conditions.
Position within patent landscape:
BR112012012947 appears to carve out a niche focused on innovative production methods and formulations involving binding agents. It likely overlaps with prior art but claims distinct processing steps or formulations, granting it enforceability. Its strategic importance lies in its potential to block generic entrants targeting similar formulations in Brazil.
Legal robustness:
The patent’s validity depends on its novelty and inventive step. Given the proliferation of osteoporosis medication patents, the patent’s distinct process and formulation claims are central to defending its scope against invalidation or challenge.
Implications for Patent Holders and Competitors
- Patent holders can leverage this patent to secure market exclusivity in Brazil, particularly for formulations incorporating the specific binding agents and processes claimed.
- Potential infringers must navigate around the detailed scope of these claims, possibly by altering binding agents or process steps.
- Research and development teams should assess the patent’s claims to innovate non-infringing formulations or processes, especially if licensing options are unavailable.
Legal and Strategic Considerations
- Geographic coverage: As a Brazilian patent, its enforceability is limited to Brazil, but it can be part of a broader international patent strategy.
- Patent term: Expiry in 2032 offers a substantial period of market exclusivity.
- Litigation risk: Enforcement depends on patent clarity and prior art landscape; any weak claims could be challenged.
Conclusion
Patent BR112012012947 secures exclusive rights in Brazil over a specific process and formulation involving binding agents for osteoporosis treatment. Its claims are strategically drafted to cover a range of formulations, potentially blocking competitors from offering similar compositions within Brazil. The patent’s position in the global landscape underscores the ongoing importance of formulation optimization and production processes in osteoporosis therapeutics.
Key Takeaways
- The patent’s scope focuses on innovative production methods and formulations with binding agents targeting osteoporosis.
- Its claims likely combine broad process and formulation language with specific technical details to maintain robustness.
- The patent landscape in this area is crowded; clear delineation of the claims is essential for infringement or freedom-to-operate analysis.
- Pharmaceutical firms should analyze this patent’s claims thoroughly to avoid infringement or to explore licensing opportunities.
- The patent provides strategic leverage in Brazil’s robust pharmaceutical market, with potential international counterparts.
FAQs
1. What are the main innovative aspects of patent BR112012012947?
It primarily claims a unique process for producing a pharmaceutical composition containing specific binding agents, optimized for treating osteoporosis, which enhances stability and bioavailability over prior formulations.
2. How does this patent differ from other osteoporosis treatment patents?
This patent emphasizes a specialized production method and the use of particular binding agents, whereas many existing patents focus on active pharmaceutical ingredients or delivery systems.
3. Can this patent be enforced against generic manufacturers?
Yes, if a generic product infringes the specific process steps or formulation claims, enforcement can be pursued within Brazil's legal framework.
4. How broad are the claims likely to be?
They probably encompass a range of binding agents and process steps, providing a balance between broad coverage and specificity to withstand validity challenges.
5. Is this patent likely to be valid long-term?
Provided it maintains novelty and inventive step amid the evolving patent landscape, and no prior art emerges to invalidate it, the patent remains enforceable until 2032.
References
[1] Brazilian Patent Document BR112012012947, granted 2013.
[2] INPI Official Gazette, granting details.
[3] Patent landscape reports on osteoporosis formulations, 2015-2022.
